The relative contribution of NSAIDs and H elicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: Observations from a tertiary referral hospital in the UK between 2005 and 2010

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 1, 2012, Pages 48-56

  Musumba, C ^a   Jorgensen, A ^a   Sutton, L ^a   Van Eker, D ^a   Moorcroft, J ^b   Hopkins, M ^b   Pritchard, D M ^a   Pirmohamed, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXICAM DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DUODENUM ULCER; FEMALE; GASTRODUODENAL ULCER; GASTROSCOPY; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATIENT REFERRAL; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; STOMACH ULCER; TERTIARY HEALTH CARE; UNITED KINGDOM;

EID: 85027955424     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05118.x     Document Type: Article

References (38)

1. Kuipers EJ, Thijs JC, Festen HP,. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 59-69.
2. Marshall BJ,. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116-28.
3. Groenen MJ, Kuipers EJ, Hansen BE, Ouwendijk RJ,. Incidence of duodenal ulcers and gastric ulcers in a Western population: back to where it started. Can J Gastroenterol 2009; 23: 604-8.
4. Quan C, Talley NJ,. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol 2002; 97: 2950-61.
5. Gisbert JP, Calvet X,. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30: 791-815.
6. Sung JJ, Kuipers EJ, El-Serag HB,. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29: 938-46.
7. Lichtenstein DR, Syngal S, Wolfe MM,. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995; 38: 5-18.
8. Wolfe MM, Lichtenstein DR, Singh G,. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
9. Blower AL, Brooks A, Fenn GC, et al,. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.
10. Higham J, Kang JY, Majeed A,. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002; 50: 460-4.
11. Singh G,. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31S-8S.
12. Pirmohamed M, James S, Meakin S, et al,. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
13. Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR,. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60: 1327-35.
14. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB,. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94: 1834-40.
15. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY,. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93: 574-8.
16. Bytzer P, Teglbjaerg PS,. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis-results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96: 1409-16.
17. McColl KE, el-Nujumi AM, Chittajallu RS, et al,. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34: 762-8.
18. Arroyo MT, Forne M, de Argila CM, et al,. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004; 9: 249-54.
19. Meucci G, Di Battista R, Abbiati C, et al,. Prevalence and risk factors of Helicobacter pylori-negative peptic ulcer: a multicenter study. J Clin Gastroenterol 2000; 31: 42-7.
20. Chan HL, Wu JC, Chan FK, et al,. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc 2001; 53: 438-42.
21. Nishikawa K, Sugiyama T, Kato M, et al,. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000; 12: 635-40.
22. Chow DK, Sung JJ,. Is the prevalence of idiopathic ulcers really on the increase? Nat Clin Pract Gastroenterol Hepatol 2007; 4: 176-7.
23. McColl KE,. Helicobacter pylori-negative ulcer disease. J Gastroenterol 2000; 35 (Suppl. 12): 47-50.
24. Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez-Diaz S,. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther 2009; 30: 1039-48.
25. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M,. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993; 88: 791-804.
26. Forrest JA, Finlayson ND, Shearman DJ,. Endoscopy in gastrointestinal bleeding. Lancet 1974; 2: 394-7.
27. R Development Core Team. R: A language and environment for statistical computing: R Foundation for Statistical Computing 2010. Available at: http://www.R-project.org. Accessed July 15, 2011.
28. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM,. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007; 32: 403-7.
29. Xia HH, Phung N, Kalantar JS, Talley NJ,. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust 2000; 173: 515-9.
30. Cucino C, Sonnenberg A,. The long-term time trends of peptic ulcer and ulcerative colitis are interrelated. Am J Gastroenterol 2002; 97: 2657-62.
31. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R,. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-86.
32. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ,. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006; 4: 130-42.
33. Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS,. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010; 32: 831-9.
34. Huang JQ, Sridhar S, Hunt RH,. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
35. McColl KE,. Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer. Gastroenterol Clin North Am 2009; 38: 353-61.
36. Henry A, Batey RG,. Low prevalence of Helicobacter pylori in an Australian duodenal ulcer population: NSAIDitis or the effect of ten years of H. pylori treatment? Aust N Z J Med 1998; 28: 345.
37. Ho B, Marshall BJ,. Accurate diagnosis of Helicobacter pylori. Serologic testing. Gastroenterol Clin North Am 2000; 29: 853-62.
38. Laheij RJ, Straatman H, Jansen JB, Verbeek AL,. Evaluation of commercially available Helicobacter pylori serology kits: a review. J Clin Microbiol 1998; 36: 2803-9.